1[1]Thigpen JT,Herrin VE.Recent developments in the treatment of recurrent ovarian carcinoma.In Stephen CR and Gregory PS ed:Ovarian Cancer.Second edition.2001.301-314.
2[2]Eng-Hseon Tay,Peter T,Grant Val Gebski,et al.Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Obstet Gynecol,2002,99:1008-1013.
3[3]Murakami M,Miyamoto T,Lida T,et al.Whole-body positron emission tomography and tumor marker CA125 for detection of recurrent in epithelial ovarian cancer.Int J Gynecol Cancer,2006,16:99-107.
4[4]David G.Mutch.Surgical Management of Ovarian Cancer.Semin Oncol,2002,29(suppl 1):3-8.
5[5]Eisenkop SM,Fredman RL,Spirtos NM,et al,The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer,2000,88:144-153.
6[6]Odicino FE,Katsaros D,Pignata S,et al.Extending the platinum-free interval (PFI)with a non-platinum therapy in platinum (P)-sensitive recurrent ovarian cancer(OC):results from the Socrates retrospective study.Int J Gynecol cancer,2006; 16(suppl 3):601.
7[7]Alberts DS.Treatment of refractory and recurrent ovarian cancer.Semin-Oncol,1999,26(1 suppl 1):8-14.
8[8]Erickson F.Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum.Gynecol Oncol,2001,80:213-220.
9[9]Berek JS,Taylor PT,Gordon A,et al.Randomized,placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.J Clin Oncol,2004,22:3507-3516.
10[10]Reinartz S,Kohler S,Schlebusch H,et al.Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125:immunological response and survival (phase Ⅰb/Ⅱ).Clin Cancer Res,2004,10:1580-1587.
9Muteh D G, Orlando M, Goss T, et al. Randomized phase Ⅲ trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer[J]. J Clin Oneol, 2007, 25(19): 2811 -2818.
10Ferrandina G, LudovisiM, Lorusso D, et al. Phase Ⅲtrial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer[J]. J Clin Oncol, 2008, 26(6):890-896.
